COST-EFFECTIVENESS OF PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC ESOPHAGEAL CANCER OR HER2-NEGATIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA IN FRANCE

被引：0
|
作者：
Aparicio, T. [1 ]
Mackosso, C. [2 ]
Cagnan, L. [3 ]
Bensimon, L. [3 ]
Tehard, B. [4 ]
Boussahoua, M. [4 ]
Zhang, S. [5 ]
Qu, T. [6 ]
Meng, Y. [7 ]
Francois, E. [8 ]
机构：
[1] St Louis Hosp, Paris, NJ, France
[2] MSD France, Puteaux La Defense, France
[3] MSD France, Paris, France
[4] Vyoo Agcy, Paris 75, France
[5] Merck, Rahway, NJ USA
[6] Luminaty, Bethesda, MD USA
[7] Luminaty, Las Vegas, NV USA
[8] Ctr Antoine Lacassagne, Nice, France
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE284
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [21] Pembrolizumab plus chemotherapy as first-line treatment in patients with HER2 negative advanced oesogastric adenocarcinoma
    Duval, Martin
    Zaanan, Aziz
    [J]. BULLETIN DU CANCER, 2024, 111 (05) : 431 - 432
  • [22] Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
    Zheng, Zhiwei
    Fang, Ling
    Cai, Hongfu
    [J]. BMC CANCER, 2023, 23 (01)
  • [23] Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
    Zhiwei Zheng
    Ling Fang
    Hongfu Cai
    [J]. BMC Cancer, 23
  • [24] Cost-effectiveness of pembrolizumab plus platinum and fluoropyrimidine-based chemotherapy as first-line treatment of advanced esophageal cancer in the United States
    Qu, T.
    Zhong, Y.
    Zhang, S.
    Meng, Y.
    Joo, S.
    Shah, S.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1059 - S1060
  • [25] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN GREECE
    Yfantopoulos, N.
    Gountas, I
    Athanasopoulos, C.
    Haiderali, A.
    Huang, M.
    Skroumpelos, A.
    Karokis, A.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S184 - S184
  • [26] Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [27] Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis
    Zheng, Zhiwei
    Song, Xiaobing
    Cai, Hongfu
    Zhu, Huide
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 1017 - 1025
  • [28] Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China
    Xiang, Zuojuan
    Ma, Ling
    Fu, Yingzhou
    Pan, Yong
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [29] Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
    Ye, Zhuo-Miao
    Xu, Zhe
    Zeng, Fan-Yuan
    Tang, Zi-Qing
    Zhou, Qin
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [30] Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
    Urakci, Zuhat
    Ebinc, Senar
    Tunc, Sezai
    Kalkan, Ziya
    Oruc, Zeynep
    Kucukoner, Mehmet
    Kaplan, Muhammet Ali
    Isikdogan, Abdurrahman
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
12345